Genitourinary Cancer
Latest News
Is this the best screening test for prostate cancer?
Researchers from the United Kingdom found that half of men with apparently “safe” PSA levels had clinically significant prostate cancers when...
Latest News
BCR is unreliable surrogate for overall survival in prostate cancer
The correlation between BCR-free survival and overall survival ranged from low to moderate.
Latest News
Predicting prostate cancer risk: Are polygenic risk scores ready for prime time?
“A polygenic risk score estimates your risk by adding together the number of bad cards you were dealt by the impact of each card, such as an ace...
From the Journals
Do AI chatbots give reliable answers on cancer? Yes and no
“The chatbot was most likely to mix in incorrect recommendations among correct ones, an error difficult even for experts to detect.”
From the Journals
Urine test shows promise for diagnosing urothelial carcinoma
“The idea is that this could be used as kind of a first-pass screening tool for patients with hematuria that could potentially obviate the need...
Feature
New trials in prostate cancer: Could your patient benefit?
Several new trials have opened in recent months.
News from the FDA/CDC
FDA OKs combo therapy of niraparib, abiraterone acetate for prostate cancer
This new agent "brings an important treatment option to patients with prostate cancer as they consider their road ahead."
Feature
How useful are circulating tumor cells for early diagnosis?
Their link with metastases, and thus with aggressive tumors, gives them an advantage over other (noninvasive or minimally invasive) biomarkers in...
From the Journals
Short bursts of activity may cut cancer risk
Examples of such activity are vigorous housework, carrying heavy shopping bags around the grocery store, bursts of power walking, and playing high...
From the Journals
MRI-guided SBRT cuts radiation toxicity in prostate cancer
“These findings suggest that the technical advantages in precision of radiotherapy delivery afforded by MRI-guided SBRT translate to measurable...
Conference Coverage
‘Treatment holiday’ in prostate cancer with tailored dosing
“Personalizing dosing intervals using early-response biomarkers with 177Lu-PSMA has the potential to achieve similar overall treatment...